Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do dopamine agonists or levodopa modify Parkinson's disease progression?

K Marek1, D Jennings, J Seibyl

  • 1The Institute for Neurodegenerative Disorders, New Haven, CT 06510, USA. kmarek@indd.org

European Journal of Neurology
|December 5, 2002
PubMed
Summary

Dopamine agonists may slow Parkinson's disease progression compared to levodopa, as shown by neuroimaging studies. Further research is needed to confirm these findings with clinical outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 vaccination uptake in people with epilepsy in wales.

Seizure·2023
Same author

Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2019
Same author

Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder.

NPJ Parkinson's disease·2019
Same author

Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study.

The journal of prevention of Alzheimer's disease·2017
Same author

High prevalence of Seoul hantavirus in a breeding colony of pet rats.

Epidemiology and infection·2017
Same author

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Movement disorders : official journal of the Movement Disorder Society·2017

Area of Science:

  • Neuroscience
  • Radiology
  • Pharmacology

Background:

  • In vivo imaging of the nigrostriatal dopaminergic system monitors Parkinson's disease (PD) progression.
  • Assessing medication effects on imaging outcomes is crucial for PD management.

Purpose of the Study:

  • To compare the effects of initial treatment with dopamine agonists versus levodopa on PD progression using neuroimaging.
  • To evaluate the rate of dopaminergic neuron loss in early PD patients under different treatment regimens.

Main Methods:

  • Two studies utilized [123I]beta-CIT and [18F]Dopa imaging to assess dopaminergic function.
  • Compared imaging outcomes in early PD patients treated with pramipexole or ropinirole against levodopa.

Main Results:

Related Experiment Videos

  • Both studies indicated a slower rate of dopaminergic uptake loss in patients treated with dopamine agonists compared to levodopa.
  • Relative reduction in [123I]beta-CIT uptake loss was 47% at 22 months with pramipexole vs. levodopa.
  • Relative reduction in [18F]Dopa uptake loss was 35% at 24 months with ropinirole vs. levodopa.

Conclusions:

  • Neuroimaging suggests dopamine agonists may slow dopaminergic neuron loss in early PD more than levodopa.
  • Results require cautious interpretation; larger, placebo-controlled studies with clinical endpoints are necessary.
  • Further research should integrate imaging outcomes with clinical measures for comprehensive PD progression assessment.